Tag Archives: CLBS

Chardan Capital Reiterates a Buy Rating on Caladrius Biosciences (CLBS)

In a report released today, Keay Nakae from Chardan Capital reiterated a Buy rating on Caladrius Biosciences (CLBS – Research Report), with a price target of $6.00. The company’s shares closed last Thursday at $1.70. According to TipRanks.com, Nakae is

H.C. Wainwright Sticks to Their Buy Rating for Caladrius Biosciences (CLBS)

In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Caladrius Biosciences (CLBS – Research Report), with a price target of $18.50. The company’s shares closed last Thursday at $1.85. According to TipRanks.com, Pantginis is

Monday’s Midday Movers: American Green Inc (ERBB), ImmunoCellular Therapeutics (IMUC), Fuelcell Energy (FCEL), Cytori Therapeutics Inc (CYTX), Caladrius Biosciences (CLBS)

So far Monday, July 15, NASDAQ is down -0.4% and the S&P is down -0.82%. Let’s take a look at this morning’s most active stocks and their recent analyst insights; American Green Inc (ERBB – Research Report), ImmunoCellular Therapeutics (IMUC

Tuesday’s Midday Movers: Anthera Pharmaceuticals (ANTH), Pixelworks (PXLW), Kandi Technologies (KNDI), LendingClub Corp (LC), Caladrius Biosciences (CLBS)

So far Tuesday, July 9, NASDAQ is up 3.23% and the S&P is up 1.2%. Let’s take a look at this morning’s most active stocks and their recent analyst insights; Anthera Pharmaceuticals (ANTH – Research Report), Pixelworks (PXLW – Research

Analysts Offer Insights on Services Companies: Caladrius Biosciences (NASDAQ: CLBS) and Zillow Group Inc (NASDAQ: ZG)

Companies in the Services sector have received a lot of coverage today as analysts weigh in on Caladrius Biosciences (CLBS – Research Report) and Zillow Group Inc (ZG – Research Report). Caladrius Biosciences (CLBS) Chardan Capital analyst Keay Nakae reiterated

H.C. Wainwright Reaffirms Their Buy Rating on Caladrius Biosciences (CLBS)

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Caladrius Biosciences (CLBS – Research Report) today and set a price target of $18.50. The company’s shares opened today at $4.55. Pantginis noted: “Valuation and risks to price target achievement;